Situofan has built a complete biopharmaceutical technology ecosystem, with core products including Ä KTA purification system, Xcellerex bioreactor, FlexFactory flexible factory, etc. The company provides customers with full cycle support from process development to commercial production through the "Fast Trak" technology training center and the "CytoVerse" digital platform. SITOFAN has deep cooperation with companies such as Moderna, playing a key role in the production of COVID-19 vaccines. Its technology has cumulatively assisted in the production of over 80% of the world's marketed antibody drugs.

In 2023, SITOFAN's global revenue exceeded 5 billion US dollars, and the Shanghai Biopharmaceutical Base, which was built with an investment of 250 million US dollars in China, has been put into operation. The company is accelerating its layout in cutting-edge fields such as continuous flow production (CFD), cell and gene therapy (CGT), and collaborating with Amazon Web Services to develop AI solutions for biopharmaceuticals. We plan to invest $1 billion in the next five years to expand our supply chain in Asia, with the goal of becoming a "full industry chain enabler" for biopharmaceuticals. The recently launched KUBio modular factory solution has further lowered the entry threshold for biopharmaceutical production.